xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT06024824</url>
    </required_header>
    <id_info>
      <org_study_id>CTRIAL-IE 17-12</org_study_id>
      <nct_id>NCT06024824</nct_id>
    </id_info>
    <brief_title>Dose-Painted Intensity Modulated Radiotherapy Pancreas (DP-IMRT Pancreas)</brief_title>
    <official_title>DP-IMRT Pancreas: A Non-randomised Phase I/II Study of Dose-escalated Hypofractionated Dose-Painted Intensity Modulated Radiotherapy (DPIMRT) in Resectable/Borderline Resectable Pancreatic Adenocarcinoma</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>Cancer Trials Ireland</agency>
        <agency_class>Other</agency_class>
      </lead_sponsor>
    </sponsors>
    <source>Cancer Trials Ireland</source>
    <oversight_info>
      <has_dmc>No</has_dmc>
      <is_fda_regulated_drug>No</is_fda_regulated_drug>
      <is_fda_regulated_device>No</is_fda_regulated_device>
    </oversight_info>
    <brief_summary>
      <textblock>
        This is a prospective non-randomised Phase I/II Radiotherapy (RT) study with patients&#xD;
        recruited to escalated dose cohorts. Patients with resectable or borderline resectable (per&#xD;
        the National Comprehensive Cancer Network (NCCN) criteria) pancreatic adenocarcinoma will&#xD;
        receive dose-escalated hypofractionated DP-IMRT via Intensity Modulated Radiotherapy (IMRT) /&#xD;
        Volume Modulated Arc Therapy (VMAT).&#xD;
      </textblock>
    </brief_summary>
    <detailed_description>
      <textblock>
        The study treatment is radiotherapy. Different doses of radiotherapy will be given to&#xD;
        patients. The first group of patients will receive the lowest dose (dose level 1) (this is&#xD;
        the dose delivered to patients as standard of care). If the treatment does not cause serious&#xD;
        side effects, it will be given to the next group of patients enrolled at a higher dose (dose&#xD;
        level 2) (this is called 'dose escalation'). If this higher dose of treatment does not cause&#xD;
        serious side effects, the next group of patients will receive a higher dose (dose level 3).&#xD;
        The doses will continue to increase for every group of patients, as long as no serious side&#xD;
        effects occur. If this happens, the study is halted. Once the optimum dose level has been&#xD;
        reached, a larger cohort of patients will all receive this dose.&#xD;
  &#xD;
        Phase I: A 3+3 dose escalation design is proposed to determine the maximum tolerated dose&#xD;
        (MTD) defined by the number of radiotherapy-related ≥ Grade 3 acute toxicities assessed up to&#xD;
        4 weeks post RT. Three cohorts of between 3 and 6 patients at each dose level will be accrued&#xD;
        in order to establish the MTD (minimum of 6, maximum of 18 patients). The MTD defined in&#xD;
        Phase I will be the dose which will be used in Phase II of the trial. Phase II: 49 patients:&#xD;
        Once the MTD is established, patients will continue to be recruited at that dose level up to&#xD;
        a total of 49 patients.&#xD;
      </textblock>
    </detailed_description>
    <overall_status>Not yet recruiting</overall_status>
    <start_date type="Anticipated">September 2023</start_date>
    <completion_date type="Anticipated">July 2031</completion_date>
    <primary_completion_date type="Anticipated">July 2027</primary_completion_date>
    <phase>Phase 1/Phase 2</phase>
    <study_type>Interventional</study_type>
    <has_expanded_access>No</has_expanded_access>
    <study_design_info>
      <allocation>Non-Randomized</allocation>
      <intervention_model>Single Group Assignment</intervention_model>
      <primary_purpose>Treatment</primary_purpose>
      <masking>None (Open Label)</masking>
      <masking_description>This is a prospective non-randomised Phase I/II Radiotherapy (RT) study with patients recruited to escalated dose cohorts. Patients with resectable or borderline resectable (per the National Comprehensive Cancer Network (NCCN) criteria) pancreatic adenocarcinoma will receive dose-escalated hypofractionated DP-IMRT via Intensity Modulated Radiotherapy (IMRT) / Volume Modulated Arc Therapy (VMAT).</masking_description>
    </study_design_info>
    <primary_outcome>
      <measure>Phase 1 - to establish the MTD in a dose-escalated and hypofractionated RT regime delivered via IMRT/VMAT by the number of DLTs</measure>
      <time_frame>4 weeks</time_frame>
      <description>To establish the MTD in a dose-escalated and hypofractionated RT regime delivered via IMRT/VMAT by the number of DLTs, and the rate of patient withdrawal from trial treatment due to DLTs. Analysis will be performed for each cohort after all patients have been assessed for their 4-week post RT assessment.</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Phase 2 - to determine the frequency and severity of DLTs due to AE/Toxicity meeting definition of DLT at 4 weeks post RT</measure>
      <time_frame>4 weeks</time_frame>
      <description>The rate of DLTs up to 4 weeks post RT will be calculated. This proportion along with the 90% confidence intervals will be reported.</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Phase 2 - to determine the rate of patient withdrawal from trial treatment due to AE/Toxicity meeting definition of DLT at 4 weeks post RT</measure>
      <time_frame>4 weeks</time_frame>
      <description>The rate of withdrawal from trial treatment of patients due to DLTs will be calculated. This proportion along with the 90% Confidence Interval will be reported. Other toxicity data including SAEs will be summarised and presented in tabular format with proportions plus 95% Confidence Interval where appropriate.</description>
    </primary_outcome>
    <secondary_outcome>
      <measure>To quantify the percentage of histologically proven R0 resections in the trial patient group (R0 to be defined as a minimal clearance of at least1 mm).</measure>
      <time_frame>2 years</time_frame>
      <description>The percentage of histologically proven R0 resections in this patient group (R0 to be defined as a minimal clearance of at least 1 mm) will be presented with 95% Confidence Interval.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>To determine the rate of failure to progress to surgery due to disease progression during neoadjuvant radiotherapy, and conversely the proportion of patients who do receive surgical resection</measure>
      <time_frame>2 years</time_frame>
      <description>The rate of failure to progress to surgery due to disease progression during neoadjuvant radiotherapy will be presented with 95% Confidence Interval. The rate of progression to surgery will be presented with 95% CI. The proportion of patients who receive surgical resection overall will be presented with 95% Confidence Interval.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>To document the proportion of peri-operative complications</measure>
      <time_frame>2 years</time_frame>
      <description>The proportion of patients with peri-operative complications will be presented with 95% Confidence Interval.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>To evaluate the impact of treatment on OS, overall and by resectability (whether resectable or borderline resectable)</measure>
      <time_frame>2 years</time_frame>
      <description>The Kaplan-Meier method will be used to estimate OS. This will be expressed as median survival with 95% Confidence Interval and will be analysed after patients have been followed for two years after completion of study treatment. The Log-rank test will be used to compare differences in survival between resectable and borderline resectable patients.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>To evaluate the impact of treatment on PFS, overall and by resectability (whether resectable or borderline resectable)</measure>
      <time_frame>2 years</time_frame>
      <description>The Kaplan-Meier method will be used to estimate PFS. This will be expressed as median survival with 95% Confidence Interval and will be analysed after patients have been followed for two years after completion of study treatment. The Log-rank test will be used to compare differences in survival between resectable and borderline resectable patients.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>To evaluate tumour response on surgically resected patients using resected specimens</measure>
      <time_frame>2 years</time_frame>
      <description>The proportion of surgically resected patients receiving at least 14 fractions of RT with tumour response using the resected specimens will be presented with 95% Confidence Interval.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>To evaluate Quality of Life</measure>
      <time_frame>2 years</time_frame>
      <description>The mean (and standard deviation) of the overall and domain specific European Organisation for Research and Treatment for Cancer (EORTC) Quality Life Questionnaire (QLQ) C30 scores at each time point will be reported (pre-chemotherapy, pre-RT, pre-surgery, 6-, 12- and 24-months post RT).&#xD;
  The EORTC QLQ C30 questionnaire has five functioning subscale scores and nine symptoms subscale scores.&#xD;
  Minimum value = 0; Max value = 100 Function Scales: Higher numbers mean better function Symptom Scale: Higher numbers mean more symptoms</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>To evaluate Quality of Life</measure>
      <time_frame>2 years</time_frame>
      <description>The mean (and standard deviation) of the overall and domain specific European Organisation for Research and Treatment for Cancer (EORTC) Quality Life Questionnaire (QLQ) PAN 26 scores at each time point will be reported (pre-chemotherapy, pre-RT, pre-surgery, 6-, 12- and 24-months post RT).&#xD;
  The EOTRC QLQ PAN 26 questionnaire is a tumour specific quality of life questionnaire for patients with pancreatic cancer.&#xD;
  Minimum value = 0; Max value = 100 Function Scales: Higher numbers mean better function Symptom Scale: Higher numbers mean more symptoms</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>To evaluate the incidence of late GI toxicities in patients who do not undergo surgical resection</measure>
      <time_frame>2 years</time_frame>
      <description>The incidence of late toxicity at 6-, 12- and 24-months post-RT, in patients who do not undergo surgical resection, will be calculated, summarised and presented in tabular format with proportions plus 95% Confidence Interval where appropriate. Toxicities of ≥ Grade 2 are of specific interest. Counts and frequencies will be provided for the worst grade AE experienced</description>
    </secondary_outcome>
    <number_of_arms>1</number_of_arms>
    <enrollment type="Anticipated">49</enrollment>
    <condition>Pancreatic Adenocarcinoma</condition>
    <arm_group>
      <arm_group_label>Radiation; IMRT</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>Fifteen fractions of external beam radiation therapy (EBRT) delivered via IMRT/ VMAT. Cohort 1 (n = 3-6) Single PTV 40.05 Gy/15#, homogenous dose* Cohort 2 (n = 3-6) High Risk PTV 45 Gy/15# SIB to PTV tumour, Elective PTV 40.05 Gy/15# to nodal regions* Cohort 3 (n = 3-6) High risk PTV 48 Gy/15# SIB to PTV tumour, Elective PTV 40.05 Gy/15# to nodal regions&#xD;
  * Progression to the next dose in successive cohorts depends on the number of patients experiencing DLTs within 4 weeks post-RT treatment in each patient cohort.</description>
    </arm_group>
    <intervention>
      <intervention_type>Radiation</intervention_type>
      <intervention_name>Dose-Painted Intensity Modulated Radiotherapy</intervention_name>
      <description>Fifteen fractions of external beam radiation therapy (EBRT) delivered via IMRT/ VMAT.&#xD;
  Cohort 1 (n = 3-6) Single PTV 40.05 Gy/15#, homogenous dose. Cohort 2 (n = 3-6) High Risk PTV 45 Gy/15# SIB to PTV tumour, Elective PTV 40.05 Gy/15# to nodal regions.&#xD;
  Cohort 3 (n = 3-6) High risk PTV 48 Gy/15# SIB to PTV tumour, Elective PTV 40.05 Gy/15# to nodal regions.</description>
      <arm_group_label>Radiation; IMRT</arm_group_label>
    </intervention>
    <eligibility>
      <criteria>
        <textblock>
          Inclusion Criteria&#xD;
  &#xD;
            1. Written informed consent obtained prior to any study-related procedures&#xD;
  &#xD;
            2. Age ≥18 years&#xD;
  &#xD;
            3. ECOG (European Cooperative Oncology Group) performance status (PS) 0-2&#xD;
  &#xD;
            4. Resectable or borderline resectable per National Comprehensive Cancer Network (NCCN)&#xD;
               criteria (see Appendix H)&#xD;
  &#xD;
            5. Patients with histologically confirmed Pancreatic Ductal Adenocarcinoma (PDAC), with&#xD;
               the following staging: cT1N0-2, cT2N0-2, cT3N0-2 [American Joint Committee on Cancer&#xD;
               (AJCC) 8th edition] (see Appendix C) who are planned for pre-operative systemic&#xD;
               chemo-radiotherapy&#xD;
  &#xD;
            6. Imaging with Computed Tomography Thorax Abdomen and Pelvis (CT TAP) and Magnetic&#xD;
               resonance imaging (MRI) Abdomen confirms no evidence of metastatic disease&#xD;
  &#xD;
            7. Females of child-bearing potential (see Appendix G) must not be pregnant (or&#xD;
               lactating) and must be prepared to use adequate contraception methods during&#xD;
               treatment. Males whose female partners are of child-bearing potential must be prepared&#xD;
               to use adequate contraception methods during treatment.&#xD;
  &#xD;
          Exclusion Criteria&#xD;
  &#xD;
            1. Previous thoracic or abdominal or pelvic radiation therapy (RT)&#xD;
  &#xD;
            2. Previous treatment for bilirubin regression, other than stenting&#xD;
  &#xD;
            3. Known co-existing or prior malignancy within the last 5 years (except for Basal Cell&#xD;
               Carcinoma (BCC) or Squamous Cell Carcinoma (SCC) of the skin) which is likely to&#xD;
               interfere with treatment or assessment of outcomes&#xD;
  &#xD;
            4. Syndromes or conditions associated with increased radiosensitivity&#xD;
  &#xD;
            5. Uncontrolled intercurrent illness that is likely to interfere with treatment or&#xD;
               assessment of outcomes, or psychiatric illness/ social situations that would limit&#xD;
               compliance with study requirements&#xD;
  &#xD;
            6. Evidence of any other significant clinical disorder or laboratory findings that makes&#xD;
               it undesirable for the patient to participate in the study, or if it is felt by the&#xD;
               research/ Medical team that the patient may not be able to comply with the protocol&#xD;
               and follow up schedule due to psychological, familial, sociological or geographical&#xD;
               conditions&#xD;
        </textblock>
      </criteria>
      <gender>All</gender>
      <minimum_age>18 Years</minimum_age>
      <maximum_age>N/A</maximum_age>
      <healthy_volunteers>No</healthy_volunteers>
    </eligibility>
    <overall_contact>
      <last_name>Cancer Trials Ireland</last_name>
      <phone>+35316677211</phone>
      <email>info@cancertrials.ie</email>
    </overall_contact>
    <location>
      <facility>
        <name>St Luke's Radiation Oncology Network (SLRON)</name>
        <address>
          <city>Dublin</city>
          <country>Ireland</country>
        </address>
      </facility>
      <contact>
        <last_name>Dr Gerard McVey</last_name>
      </contact>
    </location>
    <location_countries>
      <country>Ireland</country>
    </location_countries>
    <verification_date>August 2023</verification_date>
    <study_first_submitted>June 16, 2023</study_first_submitted>
    <study_first_submitted_qc>August 29, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">September 6, 2023</study_first_posted>
    <last_update_submitted>August 29, 2023</last_update_submitted>
    <last_update_submitted_qc>August 29, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">September 6, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Sponsor</responsible_party_type>
    </responsible_party>
    <condition_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Adenocarcinoma</mesh_term>
    </condition_browse>
    <patient_data>
      <sharing_ipd>No</sharing_ipd>
    </patient_data>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT06024824
  org study id: CTRIAL-IE 17-12
  nct id: NCT06024824
  lead sponsor: 
  has dmc: No
  is fda regulated drug: No
  is fda regulated device: No
  This is a prospective non-randomised Phase I/II Radiotherapy (RT) study with patients
        recruited to escalated dose cohorts. Patients with resectable or borderline resectable (per
        the National Comprehensive Cancer Network (NCCN) criteria) pancreatic adenocarcinoma will
        receive dose-escalated hypofractionated DP-IMRT via Intensity Modulated Radiotherapy (IMRT) /
        Volume Modulated Arc Therapy (VMAT).
  The study treatment is radiotherapy. Different doses of radiotherapy will be given to
        patients. The first group of patients will receive the lowest dose (dose level 1) (this is
        the dose delivered to patients as standard of care). If the treatment does not cause serious
        side effects, it will be given to the next group of patients enrolled at a higher dose (dose
        level 2) (this is called 'dose escalation'). If this higher dose of treatment does not cause
        serious side effects, the next group of patients will receive a higher dose (dose level 3).
        The doses will continue to increase for every group of patients, as long as no serious side
        effects occur. If this happens, the study is halted. Once the optimum dose level has been
        reached, a larger cohort of patients will all receive this dose.
  
        Phase I: A 3+3 dose escalation design is proposed to determine the maximum tolerated dose
        (MTD) defined by the number of radiotherapy-related ≥ Grade 3 acute toxicities assessed up to
        4 weeks post RT. Three cohorts of between 3 and 6 patients at each dose level will be accrued
        in order to establish the MTD (minimum of 6, maximum of 18 patients). The MTD defined in
        Phase I will be the dose which will be used in Phase II of the trial. Phase II: 49 patients:
        Once the MTD is established, patients will continue to be recruited at that dose level up to
        a total of 49 patients.
  allocation: Non-Randomized
  intervention model: Single Group Assignment
  primary purpose: Treatment
  masking: None (Open Label)
  masking description: This is a prospective non-randomised Phase I/II Radiotherapy (RT) study with patients recruited to escalated dose cohorts. Patients with resectable or borderline resectable (per the National Comprehensive Cancer Network (NCCN) criteria) pancreatic adenocarcinoma will receive dose-escalated hypofractionated DP-IMRT via Intensity Modulated Radiotherapy (IMRT) / Volume Modulated Arc Therapy (VMAT).
  measure: Phase 1 - to establish the MTD in a dose-escalated and hypofractionated RT regime delivered via IMRT/VMAT by the number of DLTs
  time frame: 4 weeks
  description: To establish the MTD in a dose-escalated and hypofractionated RT regime delivered via IMRT/VMAT by the number of DLTs, and the rate of patient withdrawal from trial treatment due to DLTs. Analysis will be performed for each cohort after all patients have been assessed for their 4-week post RT assessment.
  measure: Phase 2 - to determine the frequency and severity of DLTs due to AE/Toxicity meeting definition of DLT at 4 weeks post RT
  time frame: 4 weeks
  description: The rate of DLTs up to 4 weeks post RT will be calculated. This proportion along with the 90% confidence intervals will be reported.
  measure: Phase 2 - to determine the rate of patient withdrawal from trial treatment due to AE/Toxicity meeting definition of DLT at 4 weeks post RT
  time frame: 4 weeks
  description: The rate of withdrawal from trial treatment of patients due to DLTs will be calculated. This proportion along with the 90% Confidence Interval will be reported. Other toxicity data including SAEs will be summarised and presented in tabular format with proportions plus 95% Confidence Interval where appropriate.
  measure: To quantify the percentage of histologically proven R0 resections in the trial patient group (R0 to be defined as a minimal clearance of at least1 mm).
  time frame: 2 years
  description: The percentage of histologically proven R0 resections in this patient group (R0 to be defined as a minimal clearance of at least 1 mm) will be presented with 95% Confidence Interval.
  measure: To determine the rate of failure to progress to surgery due to disease progression during neoadjuvant radiotherapy, and conversely the proportion of patients who do receive surgical resection
  time frame: 2 years
  description: The rate of failure to progress to surgery due to disease progression during neoadjuvant radiotherapy will be presented with 95% Confidence Interval. The rate of progression to surgery will be presented with 95% CI. The proportion of patients who receive surgical resection overall will be presented with 95% Confidence Interval.
  measure: To document the proportion of peri-operative complications
  time frame: 2 years
  description: The proportion of patients with peri-operative complications will be presented with 95% Confidence Interval.
  measure: To evaluate the impact of treatment on OS, overall and by resectability (whether resectable or borderline resectable)
  time frame: 2 years
  description: The Kaplan-Meier method will be used to estimate OS. This will be expressed as median survival with 95% Confidence Interval and will be analysed after patients have been followed for two years after completion of study treatment. The Log-rank test will be used to compare differences in survival between resectable and borderline resectable patients.
  measure: To evaluate the impact of treatment on PFS, overall and by resectability (whether resectable or borderline resectable)
  time frame: 2 years
  description: The Kaplan-Meier method will be used to estimate PFS. This will be expressed as median survival with 95% Confidence Interval and will be analysed after patients have been followed for two years after completion of study treatment. The Log-rank test will be used to compare differences in survival between resectable and borderline resectable patients.
  measure: To evaluate tumour response on surgically resected patients using resected specimens
  time frame: 2 years
  description: The proportion of surgically resected patients receiving at least 14 fractions of RT with tumour response using the resected specimens will be presented with 95% Confidence Interval.
  measure: To evaluate Quality of Life
  time frame: 2 years
  description: The mean (and standard deviation) of the overall and domain specific European Organisation for Research and Treatment for Cancer (EORTC) Quality Life Questionnaire (QLQ) C30 scores at each time point will be reported (pre-chemotherapy, pre-RT, pre-surgery, 6-, 12- and 24-months post RT).
  The EORTC QLQ C30 questionnaire has five functioning subscale scores and nine symptoms subscale scores.
  Minimum value = 0; Max value = 100 Function Scales: Higher numbers mean better function Symptom Scale: Higher numbers mean more symptoms
  measure: To evaluate Quality of Life
  time frame: 2 years
  description: The mean (and standard deviation) of the overall and domain specific European Organisation for Research and Treatment for Cancer (EORTC) Quality Life Questionnaire (QLQ) PAN 26 scores at each time point will be reported (pre-chemotherapy, pre-RT, pre-surgery, 6-, 12- and 24-months post RT).
  The EOTRC QLQ PAN 26 questionnaire is a tumour specific quality of life questionnaire for patients with pancreatic cancer.
  Minimum value = 0; Max value = 100 Function Scales: Higher numbers mean better function Symptom Scale: Higher numbers mean more symptoms
  measure: To evaluate the incidence of late GI toxicities in patients who do not undergo surgical resection
  time frame: 2 years
  description: The incidence of late toxicity at 6-, 12- and 24-months post-RT, in patients who do not undergo surgical resection, will be calculated, summarised and presented in tabular format with proportions plus 95% Confidence Interval where appropriate. Toxicities of ≥ Grade 2 are of specific interest. Counts and frequencies will be provided for the worst grade AE experienced
  arm group label: Radiation; IMRT
  arm group type: Experimental
  description: Fifteen fractions of external beam radiation therapy (EBRT) delivered via IMRT/ VMAT. Cohort 1 (n = 3-6) Single PTV 40.05 Gy/15#, homogenous dose* Cohort 2 (n = 3-6) High Risk PTV 45 Gy/15# SIB to PTV tumour, Elective PTV 40.05 Gy/15# to nodal regions* Cohort 3 (n = 3-6) High risk PTV 48 Gy/15# SIB to PTV tumour, Elective PTV 40.05 Gy/15# to nodal regions
  * Progression to the next dose in successive cohorts depends on the number of patients experiencing DLTs within 4 weeks post-RT treatment in each patient cohort.
  intervention type: Radiation
  intervention name: Dose-Painted Intensity Modulated Radiotherapy
  description: Fifteen fractions of external beam radiation therapy (EBRT) delivered via IMRT/ VMAT.
  Cohort 1 (n = 3-6) Single PTV 40.05 Gy/15#, homogenous dose. Cohort 2 (n = 3-6) High Risk PTV 45 Gy/15# SIB to PTV tumour, Elective PTV 40.05 Gy/15# to nodal regions.
  Cohort 3 (n = 3-6) High risk PTV 48 Gy/15# SIB to PTV tumour, Elective PTV 40.05 Gy/15# to nodal regions.
  arm group label: Radiation; IMRT
  criteria: 
  gender: All
  minimum age: 18 Years
  maximum age: N/A
  healthy volunteers: No
  last name: Cancer Trials Ireland
  phone: +35316677211
  email: info@cancertrials.ie
  facility: 
  contact: 
  country: Ireland
  responsible party type: Sponsor
  mesh term: Adenocarcinoma
  sharing ipd: No